Allogene Therapeutics: Fourth Quarter Earnings Overview

Allogene Therapeutics Reports Fourth Quarter Financial Results

Allogene Therapeutics Inc., based in South San Francisco, California, announced on Thursday that it recorded a net loss of $38.8 million for the fourth quarter.

The company reported a per-share loss of 17 cents during this period.

This performance was better than what analysts had anticipated. According to Zacks Investment Research, the consensus estimate from seven analysts was a loss of 25 cents per share.

At the close of trading on Thursday, Allogene's stock price stood at $2.47, compared to $2.06 at the same time last year.